home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 11/10/20

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
KROS - Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies' IPO

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) (“SQZ”) on the New York Stock Exchange (NYSE) as of Octobe...

KROS - Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

KROS - OraSure's Emergency Use Authorization, And Other News: The Good, Bad And Ugly Of Biopharma

OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes. Affimed to collaborate with NKMax America for SNK01 natural killer cell therapy. For further details see: OraSure's Emergency Use...
KROS - Dosing underway for Keros Therapeutics's KER-050 in mid-stage for myelodysplastic syndromes study

Keros Therapeutics ([[KROS]] +5.9%) has dosed the first two participants in a Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes ((MDS)).Keros presented data from its Phase 1 clinical trial of KER-050 in healthy post-me...

KROS - Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

First two participants dosed in a Phase 2 clinical trial of KER-050 in MDS Initial data expected by mid-2021 LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS)...

KROS - U.S. IPO Week Ahead: The IPO Market Cools Off In A 2-IPO Week

Following an active September, two IPOs are scheduled to raise $200 million in the week ahead. Several companies could join the IPO calendar early in the week, such as Spruce Biosciences, Shattuck Labs, and Kronos Bio. Live TV streaming platform fuboTV plans to raise $150 million ...
KROS - Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musc...

KROS - Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...

KROS - Keros Therapeutics EPS beats by $0.06

Keros Therapeutics (NASDAQ: KROS ) : Q2 GAAP EPS of -$0.62 beats by $0.06 . cash and cash equivalents of $144.7M. Press Release More news on: Keros Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

Previous 10 Next 10